LISCure BioSciences Achieves Landmark FDA NDI for Hair Probiotics
LISCure BioSciences Achieves FDA NDI Notification for Mobiome®
LISCure BioSciences has made significant strides by announcing that Mobiome®, its innovative hair health probiotic, has received New Dietary Ingredient (NDI) notification from the U.S. Food and Drug Administration (FDA). This achievement marks the first of its kind globally, showcasing a new frontier in probiotic advancements targeting hair health.
Scientific Validation and Efficacy of Mobiome®
Prior to its FDA NDI notification, Mobiome® was recognized by the Korean Ministry of Food and Drug Safety (MFDS) as a new functional ingredient. This recognition stemmed from a series of rigorous scientific studies, including both preclinical and clinical trials, which demonstrated its multiple mechanisms of action. Research revealed that Mobiome® enhances antioxidant activity, reduces inflammation, stimulates hair follicle cell proliferation, and regulates the hair follicle cell cycle. Clinical trials highlighted statistically significant improvements in hair gloss and elasticity, as well as increased consumer satisfaction in terms of hair texture, split ends, dryness, and damage.
The Importance of NDI Notification
The FDA's NDI notification process is one of the most stringent in the dietary supplement industry. It requires comprehensive evidence that verifies the ingredient's safety and scientific efficacy. The evaluation process examines various aspects including toxicological safety and functional validation data. Achieving NDI status is crucial for companies looking to make a mark in the global dietary supplement market; it speaks volumes about the quality and reliability of the product.
Looking Ahead: Expansion Plans for LISCure
CEO Hwa-sup Chin expressed enthusiasm over the FDA's acceptance of the NDI notification for Mobiome®. He stated, "This acceptance bolsters our competitive edge not only in Korea but across the international nutraceutical landscape. We are poised to accelerate our expansion efforts in North America, Europe, and vital Asian markets." This strategic expansion is part of LISCure's commitment to delivering cutting-edge health solutions around the world.
Broader Innovations Beyond Hair Health
In addition to focusing on hair health, LISCure BioSciences is actively developing a robust pipeline of functional ingredients aimed at tackling various health concerns. This includes ingredients recognized for body fat reduction, joint health, kidney health, and cognitive improvement. LISCure is also pursuing additional FDA NDI submissions to broaden its portfolio.
Advancements in Pharmaceuticals
Parallel to its endeavors in dietary supplements, LISCure is progressing multiple programs in its core pharmaceutical business. Among these is the Brain Shuttle Platform 'ExoPN-101', a project poised for global partnership and potential licensing. Another critical candidate, LB-P8, which is targeting progressive sclerosing cholangitis (PSC), has already been granted FDA Orphan Drug Designation and Fast Track Designation. Currently, LB-P8 is in Phase 2 clinical trials in the United States.
Commitment to Innovative Health Solutions
Moreover, the immuno-oncology therapeutic candidate LB-P2D is making headway supported by robust preclinical efficacy data and is progressing towards clinical trials in the U.S. LISCure's dual focus on innovating pharmaceuticals and health supplements positions the company for sustainable growth and impactful health solutions globally.
About LISCure BioSciences
LISCure BioSciences is a forward-thinking biotechnology company dedicated to developing novel therapeutics and scientifically validated functional ingredients. With an emphasis on pharmaceutical innovation alongside health supplement commercialization, LISCure aims to enhance quality of life while contributing meaningfully to the advancement of global healthcare.
Frequently Asked Questions
What is Mobiome®?
Mobiome® is a proprietary hair health probiotic developed by LISCure BioSciences that has received FDA NDI notification.
How does Mobiome® improve hair health?
Mobiome® enhances antioxidant activity, reduces inflammation, and stimulates hair follicle cell proliferation, leading to better hair quality.
What is the significance of the FDA NDI notification?
The FDA NDI notification signifies that Mobiome® has met rigorous safety and scientific efficacy standards, crucial for dietary supplements.
In which markets is LISCure expanding?
LISCure is accelerating its expansion into North America, Europe, and key Asian markets.
What other health concerns is LISCure addressing?
In addition to hair health, LISCure is developing ingredients for body fat reduction, joint health, kidney health, and cognitive improvement.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.